SFO
IRD

Stokes Family Office’s Opus Genetics IRD Stock Holding History

Stokes Family Office’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.1K Hold
12,120
– – 0.01% 276
2025
Q4 		$24.4K Hold
12,120
– – ﹤0.01% 310
2025
Q3 		$20K Hold
12,120
– – ﹤0.01% 265
2025
Q2 		$11.4K Hold
12,120
– – ﹤0.01% 234
2025
Q1 		$11.9K Hold
12,120
– – ﹤0.01% 233
2024
Q4 		$14.4K Hold
12,120
– – ﹤0.01% 244
2024
Q3 		$15.9K Hold
12,120
– – ﹤0.01% 227
2024
Q2 		$18.5K Hold
12,120
– – ﹤0.01% 223
2024
Q1 		$24.4K Hold
12,120
– – ﹤0.01% 222
2023
Q4 		$36.5K Sell
12,120
-910
-7% -$2.69K ﹤0.01% 221
2023
Q3 		$43.7K Buy
13,030
+780
+6% +$3.13K 0.01% 338
2023
Q2 		$53.2K Buy
12,250
+130
+1% +$617 0.01% 327
2023
Q1 		$45.5K Hold
12,120
– – 0.01% 300
2022
Q4 		$42.8K Hold
12,120
– – 0.01% 274
2022
Q3 		$24K Hold
12,120
– – ﹤0.01% 271
2022
Q2 		$23K Hold
12,120
– – ﹤0.01% 271
2022
Q1 		$39K Hold
12,120
– – 0.01% 257
2021
Q4 		$45K Hold
12,120
– – 0.01% 249
2021
Q3 		$62K Hold
12,120
– – 0.01% 226
2021
Q2 		$64K Hold
12,120
– – 0.01% 217
2021
Q1 		$70K Buy
+12,120
New +$113K 0.01% 194

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Stokes Family Office's IRD Position: Q1 2026 in Review

Stokes Family Office held its Opus Genetics (IRD) position steady in Q1 2026 at 12,120 shares worth $55.1K. The position accounts for 0.01% of the portfolio, ranked #276.

Stokes Family Office first reported a position in IRD in Q1 2021 and has held it in 21 quarters since. The position peaked at $70K in Q1 2021. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Stokes Family Office held 12,120 shares of Opus Genetics worth $55.1K as of Q1 2026.
  • Stokes Family Office left its Opus Genetics share count unchanged in Q1 2026.
  • Opus Genetics made up 0.01% of Stokes Family Office's portfolio in Q1 2026, its #276 holding.
  • Stokes Family Office first reported a position in Opus Genetics in Q1 2021 and has held it in 21 quarters since.
  • Stokes Family Office's Opus Genetics position peaked at $70K in Q1 2021.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Stokes Family Office's 13F filing for Q1 2026, filed 12 May 2026.